磷酸化肿瘤抑制基因LATS1/LATS2抗体

Quantity size:

0.1ml

Concentration:

1mg/ml磷酸化肿瘤抑制基因LATS1/LATS2抗体  Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Background:

Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein MST1/MST2, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates磷酸化肿瘤抑制基因LATS1/LATS2抗体YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in centrosome duplication, maintenance of mitotic fidelity and genomic stability. Negatively regulates G1/S transition by down-regulating cyclin E/CDK2 kinase activity. Negative regulator of the androgen receptor.

磷酸化肿瘤抑制基因LATS1/LATS2抗体Also known as:

LATS1 +LATS2 (phospho T1079 + T1041); Serine/threonine protein kinase LATS2; KPM; Large tumor supressor, homolog 1; LATS, large tumor suppressor, homolog 1 (Drosophila); LATS, large tumor suppressor, homolog 2 (Drosophila); LATS1 +LATS2 (phospho T1079 + T1041); p-LATS1 +LATS2(Thr1079 +Thr1041); RGD1564085; Serine/threonine protein kinase LATS1; WARTS; WARTS protein kinase; wts; 4932411G09Rik; AV277261; AW208599; AW228608; FLJ13161; LATS1_HUMAN.

Specificity:

●

Rabbit Polyclonal IgG,磷酸化肿瘤抑制基因LATS1/LATS2抗体 affinity purified by Protein A.

●

Reacts with: Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, .

●

Immunogen: KLH conjugated synthesised phosphopeptide derived from human.

●

Predicted Molecular Weight: 124kDa.

磷酸化肿瘤抑制基因LATS1/LATS2抗体Storage:

Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).

Application:

WB=1:100-500  ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  IF=1:100-500   
Not yet tested in other applications. 
Optimal working dilutions must be determined by the end user.

kl060Bo01白介素13(IL13)多克隆抗体Polyclonal Antibody to Interleukin 13 (IL13)

kl060Ca01白介素13(IL13)多克隆抗体Polyclonal Antibody to Interleukin 13 (IL13)

kl060Cp01白介素13(IL13)多克隆抗体Polyclonal Antibody to Interleukin 13 (IL13)

kl060Eq01白介素13(IL13)多克隆抗体Polyclonal Antibody to Interleukin 13 (IL13)

kl060Ga01白介素13(IL13)多克隆抗体Polyclonal Antibody to Interleukin 13 (IL13)

kl060Hu01白介素13(IL13)多克隆抗体Polyclonal Antibody to Interleukin 13 (IL13)

kl060Mu01白介素13(IL13)多克隆抗体Polyclonal Antibody to Interleukin 13 (IL13)

kl060Po01白介素13(IL13)多克隆抗体Polyclonal Antibody to Interleukin 13 (IL13)

kl060Ra01白介素13(IL13)多克隆抗体Polyclonal Antibody to Interleukin 13 (IL13)

kl060Si01白介素13(IL13)多克隆抗体Polyclonal Antibody to Interleukin 13 (IL13)

kl061Bo01白介素15(IL15)多克隆抗体Polyclonal Antibody to Interleukin 15 (IL15)

kl061Cp01白介素15(IL15)多克隆抗体Polyclonal Antibody to Interleukin 15 (IL15)

kl061Fi01白介素15(IL15)多克隆抗体Polyclonal Antibody to Interleukin 15 (IL15)

kl061Ga01白介素15(IL15)多克隆抗体Polyclonal Antibody to Interleukin 15 (IL15)

kl061Gu01白介素15(IL15)多克隆抗体Polyclonal Antibody to Interleukin 15 (IL15)

kl061Hu01白介素15(IL15)多克隆抗体Polyclonal Antibody to Interleukin 15 (IL15)

kl061Mu01白介素15(IL15)多克隆抗体Polyclonal Antibody to Interleukin 15 (IL15)

kl061Po01白介素15(IL15)多克隆抗体Polyclonal Antibody to Interleukin 15 (IL15)

kl061Ra01白介素15(IL15)多克隆抗体Polyclonal Antibody to Interleukin 15 (IL15)

kl061Rb52白介素15(IL15)多克隆抗体Polyclonal Antibody to Interleukin 15 (IL15)

kl062Bo01白介素16(IL16)多克隆抗体Polyclonal Antibody to Interleukin 16 (IL16)

kl062Ga01白介素16(IL16)多克隆抗体Polyclonal Antibody to Interleukin 16 (IL16)

kl062Hu01白介素16(IL16)多克隆抗体Polyclonal Antibody to Interleukin 16 (IL16)

kl062Mu01白介素16(IL16)多克隆抗体Polyclonal Antibody to Interleukin 16 (IL16)